NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









EMulate Therapeutics

EMulate Therapeutics

Private
Bellevue, WashingtonHealthcare & Life Scienceshttps://emulatetx.com/

Last Round

Crowdfunding

Oct 28, 2025

Est. Valuation

$250M

Total Funding Raised

$733,267

Momentum

Top 50%

of companies Caplight tracks

Company Overview

EMulate Therapeutics is a healthcare company that has developed a platform using ultra-low radio frequency energy (ulRFE®) intended to provide therapeutic benefits for conditions such as cancer, pain, and mental health disorders.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials, Mental Health

Business Model

B2B

Customer Profile

Hardware + Subscription, Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

digital therapeuticsbioelectronic medicineultra-low radio frequency energyulRFEwearable medical devicenon-invasive treatmentcancer therapybio-electromagnetic technologyglioblastomadiffuse midline gliomapain managementmental health therapyHumanitarian Device ExemptionHDEanimal health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EMulate Therapeutics Comparables

Compare EMulate Therapeutics with similar companies based on industry and business-model similarity.

EMulate Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Autem Therapeutics
85%
Novocure
77%
TheraBionic
76%

EMulate Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingOct 28, 2025
IPOJul 31, 2024
Convertible DebtJul 20, 2021
Convertible DebtFeb 23, 2021
VC RoundFeb 24, 2017
Series A Extension
Feb 1, 2012

Key People

Founding team and executive leadership

Kyle Kingma

Chief Financial Officer

Executive Team

EMulate Therapeutics Investors

Notable investors and investment history

EMulate Therapeutics investors
InvestorRounds
E.F. Hutton & Co.IPO
Brookline Capital MarketsIPO

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 19, 2026

    Monthly visitors increased 65% MoM.

  • Oct 28, 2025

    $103K raised via Wefunder

EMulate Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EMulate Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EMulate Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBellevue, Washington
Employee Range13
Year Founded2002
Last FundingOct 28, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.